Article Information
History
- November 13, 2020.
Article Versions
- Version 1 (May 12, 2020 - 06:39).
- Version 2 (July 19, 2020 - 10:30).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
REVISION SUMMARY
updated manuscript and data
Author Information
- Peter Czuppon1,2,*,
- Florence Débarre2,
- Antonio Gonçalves3,
- Olivier Tenaillon3,
- Alan S. Perelson4,
- Jérémie Guedj4,*,† and
- François Blanquart2,3,*,†
- 1Institute of Ecology and Environmental Sciences of Paris, Sorbonne Université, CNRS, UPEC, IRD, INRAE, 75252 Paris, France
- 2Center for Interdisciplinary Research in Biology, CNRS, Collège de France, PSL Research University, 75005 Paris, France
- 3Université de Paris, INSERM, IAME, F-75018 Paris
- 4Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
- ↵*Corresponding author; e-mail: peter.czuppon{at}upmc.fr, jeremie.guedj{at}inserm.fr, francois.blanquart{at}college-de-france.fr
↵† These authors contributed equally.
Posted November 13, 2020.
Success of prophylactic antiviral therapy for SARS-CoV-2: predicted critical efficacies and impact of different drug-specific mechanisms of action
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
3
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos